Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
AstraZeneca
QuintilesIMS
Federal Trade Commission
Baxter
Cantor Fitzgerald
Merck
Healthtrust

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLIPIZIDE

« Back to Dashboard

Clinical Trials for Glipizide

Trial ID Title Status Sponsor Phase Summary
NCT00094770 An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
NCT00116831 Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes Completed GlaxoSmithKline Phase 3 The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
NCT00509236 Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
NCT00509262 Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
NCT00513630 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease Completed Shanghai Jiao Tong University School of Medicine Phase 4 The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study The end point of this study is: 1. follow up 3yr 2. recurrence of cardiovascular event 3. death caused by other reasons such as stroke, uremia, blindness and amputation
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Glipizide

Condition Name

Condition Name for Glipizide
Intervention Trials
Type 2 Diabetes 7
Diabetes Mellitus, Type 2 7
Type 2 Diabetes Mellitus 4
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Glipizide
Intervention Trials
Diabetes Mellitus 20
Diabetes Mellitus, Type 2 17
Renal Insufficiency, Chronic 3
Kidney Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Glipizide

Trials by Country

Trials by Country for Glipizide
Location Trials
United States 89
India 18
Mexico 13
Italy 12
Germany 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Glipizide
Location Trials
North Dakota 6
Illinois 5
California 4
Pennsylvania 4
Texas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Glipizide

Clinical Trial Phase

Clinical Trial Phase for Glipizide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 9
Phase 2 1
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Glipizide
Clinical Trial Phase Trials
Completed 24
Unknown status 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Glipizide

Sponsor Name

Sponsor Name for Glipizide
Sponsor Trials
Merck Sharp & Dohme Corp. 6
Canadian Network for Observational Drug Effect Studies, CNODES 3
Drug Safety and Effectiveness Network, Canada 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Glipizide
Sponsor Trials
Other 26
Industry 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Johnson and Johnson
UBS
Queensland Health
Accenture
Medtronic
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.